Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats
- 1 April 2000
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 85 (3), 443-450
- https://doi.org/10.1016/s0304-3959(99)00303-6
Abstract
The present study directly compared the antinociceptive and toxic effects of the neuronal nicotinic receptor agonist ABT-594 ((R)-5-(2-azetidinylmethoxy)-2-chloropyridine) with (−)-nicotine and (+)-epibatidine. Like (−)-nicotine (0.8 and 1.6 mg/kg s.c.) and (+)-epibatidine (0.005 and 0.01 mg/kg s.c.), ABT-594 (0.05 and 0.1 mg/kg s.c.) increased response latencies in the hot-plate test in rats, indicating that it has antinociceptive activity. In contrast to (−)-nicotine and (+)-epibatidine, ABT-594 did not cause rotarod impairment at antinociceptive doses but did cause hypothermia and life-threatening adverse effects including seizures. ABT-594 (0.01 and 0.1 mg/kg i.v.) also produced a dose-dependent increase in blood pressure resembling that observed with (−)-nicotine (0.03, 0.1 and 0.03 mg/kg i.v.) and (+)-epibatidine (0.001 and 0.003 mg/kg i.v.). Both the antinociceptive and toxic effects (convulsions and hypertension) were abolished by pretreatment with the brain penetrant neuronal nAChR antagonist mecamylamine (1 mg/kg s.c.; i.v. for cardiovascular studies), demonstrating that these actions of ABT-594 were mediated via activation of neuronal nicotinic receptors. Continuous infusion of ABT-594 (0.2 mg/kg per day s.c.) to rats for 7 days followed by challenge with mecamylamine (1 mg/kg i.p.) induced a nicotine-like abstinence syndrome suggesting that ABT-594 has nicotine-like dependence liability. These findings indicate that the acute safety profile of ABT-594 is not significantly improved over other nicotinic analgesics.Keywords
This publication has 16 references indexed in Scilit:
- Role of the Nucleus Raphe Magnus in Antinociception Produced by ABT-594: Immediate Early Gene Responses Possibly Linked to Neuronal Nicotinic Acetylcholine Receptors on Serotonergic NeuronsJournal of Neuroscience, 1998
- Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in miceEuropean Journal of Pharmacology, 1998
- Identification and Initial Structure−Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine ReceptorsJournal of Medicinal Chemistry, 1998
- Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine ReceptorsScience, 1998
- Nicotine and brain-stimulation reward: Interactions with morphine, amphetamine and pimozidePharmacology Biochemistry and Behavior, 1993
- Frog Venom Cocktail Yields a One-Handed PainkillerScience, 1993
- The synthesis of (+)- and (–)-epibatidineJournal of the Chemical Society, Chemical Communications, 1993
- Rodent model of nicotine abstinence syndromePharmacology Biochemistry and Behavior, 1992
- Nicotine preferentially stimulates dopamine release in the limbic system of freely moving ratsEuropean Journal of Pharmacology, 1986
- A NOVEL SYNTHESIS OF OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACIDChemistry Letters, 1973